(Total Views: 495)
Posted On: 01/11/2021 7:04:22 PM
Post# of 154115
If CD12 obtains EUA, CD12 RO is totally irrelevant.
My point is that CD12 RO is useful to drive approval if CD12 mortality reduction is only 20% and the p-value is 0.1.
I think the FDA reviewers will care about the totally new, totally original theory of leronlimab as medicine and they will be quite surprised that experimental examination of this theory was abandoned by the sponsor if that is the case.
My point is that CD12 RO is useful to drive approval if CD12 mortality reduction is only 20% and the p-value is 0.1.
I think the FDA reviewers will care about the totally new, totally original theory of leronlimab as medicine and they will be quite surprised that experimental examination of this theory was abandoned by the sponsor if that is the case.
(0)
(0)
